Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

NCT05645380 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05645380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05645380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 5, 2022
Completion date
December 31, 2028
Enrollment
139 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast cancer